Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Total transaction value of the divestment is Rs. 3,660 million
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Subscribe To Our Newsletter & Stay Updated
